Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients

Obstructive sleep apnoea (OSA) upregulates the programmed cell death-1 receptor and its ligand (PD-L1) pathway, potentially compromising immunosurveillance. We compared circulating levels of soluble PD-L1 (sPD-L1) in patients with cutaneous melanoma according to the presence and severity of OSA, and evaluated relationships with tumour aggressiveness and invasiveness.In a multicentre observational study, 360 patients with cutaneous melanoma underwent sleep studies, and serum sPD-L1 levels were assayed using ELISA. Cutaneous melanoma aggressiveness indices included mitotic rate, Breslow index, tumour ulceration, Clark level and tumour stage, and sentinel lymph node (SLN) metastasis was recorded as a marker of invasiveness.sPD-L1 levels were higher in severe OSA compared to mild OSA or non-OSA patients. In OSA patients, sPD-L1 levels correlated with Breslow index and were higher in patients with tumour ulceration, advanced primary tumour stages or with locoregional disease. The incorporation of sPD-L1 to the classic risk factors to SLN metastasis led to net improvements in the classification of 27.3%.Thus, sPD-L1 levels are increased in melanoma patients with severe OSA, and, in addition, might serve as a potential biomarker of cutaneous melanoma aggressiveness and invasiveness in this group of subjects.

Download Full-text

ASA physical status classification of obstructive sleep apnoea disease

Journal of Clinical Anesthesia ◽

10.1016/j.jclinane.2017.10.011 ◽

2018 ◽

Vol 44 ◽

pp. 19-20

Author(s):

Olumuyiwa A. Bamgbade

Keyword(s):

Obstructive Sleep Apnoea ◽

Sleep Apnoea ◽

Physical Status ◽

Physical Status Classification ◽

Obstructive Sleep ◽

Status Classification

Download Full-text

The classification of oximetry signals using Bayesian neural networks to assist in the detection of obstructive sleep apnoea syndrome

Physiological Measurement ◽

10.1088/0967-3334/31/3/007 ◽

2010 ◽

Vol 31 (3) ◽

pp. 375-394 ◽

Cited By ~ 13

Author(s):

J V Marcos ◽

R Hornero ◽

D Álvarez ◽

I T Nabney ◽

F del Campo ◽

...

Keyword(s):

Neural Networks ◽

Obstructive Sleep Apnoea ◽

Sleep Apnoea ◽

Obstructive Sleep Apnoea Syndrome ◽

Bayesian Neural Networks ◽

Sleep Apnoea Syndrome ◽

Obstructive Sleep

Download Full-text

Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea

European Respiratory Journal ◽

10.1183/13993003.01885-2017 ◽

2018 ◽

Vol 51 (3) ◽

pp. 1701885 ◽

Cited By ~ 8

Author(s):

Fernando Santamaria-Martos ◽

Ivan Benítez ◽

Cristina Girón ◽

Ferran Barbé ◽

Miguel-Angel Martínez-García ◽

...

Keyword(s):

Obstructive Sleep Apnoea ◽

Adhesion Molecule ◽

Cutaneous Melanoma ◽

Calcium Binding ◽

Tumour Growth ◽

Serum Levels ◽

Sleep Apnoea ◽

Intracellular Adhesion Molecule ◽

Obstructive Sleep ◽

Endothelial Growth Factor

The goal of this study was to assess the relationship between the severity of obstructive sleep apnoea (OSA) and the levels of carcinogenesis- and tumour growth-related biomarkers in patients with cutaneous melanoma.This multicentre observational study included patients who were newly diagnosed with melanoma. The patients were classified as non-OSA (apnoea–hypopnoea index (AHI) 0–5 events·h−1), mild OSA (AHI 5–15 events·h−1) and moderate–severe OSA (AHI >15 events·h−1). ELISAs were performed to analyse the serum levels of hypoxia- and tumour adhesion-related biomarkers (vascular endothelial growth factor (VEGF), interleukin (IL)-8, intracellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM)-1) and markers of tumour aggressiveness (S100 calcium-binding protein B (S100B) and melanoma inhibitory activity (MIA)). A logistic model adjusted for age, sex and body mass index was fitted to each biomarker, and the AHI served as the dependent variable.360 patients were included (52.2% male, median (interquartile range) age 55.5 (43.8–68.0) years and AHI 8.55 (2.8–19.5) events·h−1). The levels of VEGF, IL-8, ICAM-1, S100B and MIA were not related to the severity of OSA. The levels of VCAM-1 were higher in patients with OSA than those without OSA (mild OSA: odds ratio (OR) 2.07, p=0.021; moderate–severe OSA: OR 2.35, p=0.013).In patients with cutaneous melanoma, OSA was associated with elevated circulating levels of VCAM-1 that could indicate the contribution of OSA in tumorigenesisviaintegrin-based adhesion.

Download Full-text